Large-scale integrative studies of risk factors in coronary heart disease: from discovery to application

Lead Research Organisation: University of Cambridge
Department Name: Public Health and Primary Care

Abstract

If medical studies can reliably demonstrate that a particular factor is relevant to heart disease, then this could have important implications for the prediction and prevention of disease, as, for example, is now the case with measurement and modification of blood LDL("bad")-cholesterol levels.

Unfortunately, attempts using conventional approaches to identify risk factors that have cause-and-effect relationships with heart disease have often yielded costly failures in drug trials of new medicines.

Similarly, only modest improvements have been achieved in the prediction of heart disease with incremental modifications to conventional approaches.

Our research plan offers a fundamentally new approach to address these problems by combining the precision of molecular measurements with the power of large-scale population health studies. The deep integration of cutting-edge technologies for genetic and biochemical measurement technologies with extremely large and mature biomedical surveys ("epidemiological studies") of heart disease will yield studies that combine unprecedented power and detail.

In particular, for 50,000 people with heart attacks and 50,000 controls, we have for each participant, already recorded extensive detail about:

-genetic make-up (eg, up to one million genetic variants or "letters")
-blood biochemistry (eg, up to a few hundred analytes)
-lifestyle and other habits (eg, diet, physical activity, tobacco and alcohol consumption).

In the most informative subsets of these participants, we will conduct state-of-the-art measurements to supplement this extensive existing information. A key advantage of blood measurement methods called "lipidomics" and "metabonomics" should be that, although they relate to biochemical processes likely to be relevant to the causation of heart attacks (ie, fat and sugar metabolism, respectively), they cast wide scientific nets. This should avoid premature assumptions about the identity of the precise factors that might emerge to be relevant to heart disease.

Furthermore, as funding has already been awarded for "lipidomics" and "metabonomics" assays in 15,000 "control" participants in one of our studies (which we share with a study of new-onset type 2 diabetes), we will achieve major scientific synergy and cost savings by conducting concurrently the same assays in patients with new onset heart disease.

To help harvest the complex and rich data that will emerge from our studies in a rigorous and principled manner, our team includes world leaders in biostatistics. We will build on innovative approaches that we have previously developed to help distinguish causal from non-causal factors in heart disease.

The objective will be to discover entirely new causes of heart disease as well as to evaluate a variety of factors already suspected in heart disease, such as blood fats, sugar metabolism, "inflammation" (which is the body's response to injury), and nutritional factors.

We will use the same databases (supplemented by additional sources of information) to develop and test a range of approaches that have potential to improve the prediction of first-onset heart disease, such as those that:

-maximise accuracy of the prediction of heart disease, such as detailed scores containing genetic and biochemical information, which may be especially relevant to young people contemplating a lifetime of preventive therapy or to people with a strong family history of heart disease

-promote efficiency for health services, eg, "sequential" screening, which initially involves comparatively simple tests for everyone, then focusing more costly and detailed measurements on individuals initially identified as being most likely to benefit from further assessment.

Technical Summary

With separate funding, we have established a consortium of 50,000 first-onset CHD cases and 50,000 controls, including ~25,000 incident CHD cases and ~25,000 controls from "nested" case-control or case-cohort subsets in population-based prospective studies. All are sharing extensive individual participant data.

For all 100,000 participants, we are assaying a novel gene array (Exome+), as well as CardioMetabochip and genomewide association arrays in ~60,000 participants. These arrays furnish complementary data, enabling: i) study of >310,000 coding variants ii) dense fine-mapping of 360 priority loci (eg, >100 loci nominated by pharma, reflecting industry's priorities) iii) deep replication of previously identified promising variants and iv) imputation of 15 million additional variants.

In large subsets, we are assaying ~200 soluble biomarkers of potential vascular relevance, eg: i) a panel of phospholipid fatty acids ii) pro-atherogenic and/or pro-inflammatory lipids iii) adipocytokines, endocrine factors iv) carotenoids and vitamins.

We now propose to conduct lipidomics, metabonomics, and detailed inflammation biomarker assays in key subsets of these participants, capitalising on recent strategic investment in MRC labs.

This combination of exceptional statistical power, access to individual-level data, extensive genotyping, and extensive phenotyping should provide great opportunities for: i) discovery ii) causal analysis (using Mendelian randomisation analysis) and iii) advancement of disease prediction strategies.

To meet the challenges of analysing such exceptionally large and detailed datasets, we have assembled a world-leading analytical team led by the current, and the recent former, Directors of the MRC Biostatistics Unit. To hasten translation of findings, we have made arrangements for a variety of follow-on studies.

To execute our plan, we seek support to maintain a core subset of our existing scientific team.

Planned Impact

In addition to the academic benefits described above, this proposal has the potential to contribute to industry and public policy:

1) Industry

Our research will directly address three inter-related issues underlying the high rate of failure in medicines development: a) identification of new therapeutic targets b) validation of proposed therapeutic targets and c) stratified approaches to test new agents.

Our findings should feed swiftly into senior R&D decision-making, both at pharmaceutical companies and small and medium-sized enterprises in the biotechnology sector, because:

-industry partners (Merck, Novartis, Pfizer) have co-funded genetic assays for our 100,000-person consortium on a pre-competitive basis, and they will follow the results closely because we have regular meetings and other mechanisms in place (see Pathways to Impact)

-we will continue to work closely with industry to hasten medicines development, exemplified by establishment of the Pfizer-Cambridge Centre for CVD Genomics in our department in 2011 (which has attracted 2 MRC CASE industrial PhD awards and NIHR co-funding)

-we have regular opportunities to engage with senior industry decision-makers, eg: the CEU has strategic collaborations with several industry partners. As noted above, JD is on the international scientific advisory boards of pharmaceutical and biotechnology companies.

The enthusiasm of industry for our proposal is demonstrated by the attached letters of support from:

Merck: Dr M Mendelsohn, Global Franchise Head, Atherosclerosis and CVD, and Dr D Bloomfield, Global Head of CVD Discovery

Novartis: Dr L Letvak, Global Development Franchise Head, Critical Care, and Dr D Keefe, Global Program Head, Lipids

Pfizer: Dr T Rolph, Chief Scientific Officer, Global Cardiovascular Franchise, and Dr N Sarwar, Global Head of Population Research and CVD Genetics

Sanofi: Dr A Plump, Deputy Head of Research and Translational Medicine.

2) NHS, other healthcare providers, policy makers

Although the UK recently introduced a universal national CVD screening programme (NHS Health Check) for adults aged 40-74 years with an expected cost of £2 billion for the initial 5 years, it is acknowledged that many of its details have not been founded on robust evidence and could be optimised (or even re-designed) with emergence of new data.

More generally, there are diverse (and often divergent) guidelines from international bodies about optimum approaches to CVD risk screening, partly because of the limitations in the underpinning epidemiological studies.

Our results should contribute to screening policy because:

-we are closely engaged with translational initiatives of the UK NIHR, eg: JD is the leader of the Population Science theme of the NIHR Cambridge Biomedical Research Centre and of the stroke biomarkers theme of the NIHR Healthcare Technology Cooperative awarded to Cambridge in 2012.

-our previous results have influenced CVD screening guidelines in the USA (eg, AHA / American College of Cardiology) and in Europe (eg, European Society of Cardiology)

-we are contributing to EU initiatives in CVD risk screening as part of EC-FP7.

Organisations

Publications

10 25 50

publication icon
Armbrecht G (2015) Vertebral Scheuermann's disease in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over. in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA

 
Guideline Title ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Description ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical guidelines
 
Description Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in other policy documents
 
Description COMPARE - change in haemoglobin testing (Emanuele Di Angelantonio)
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
Impact The results of the INTERVAL trial (www.intervalstudy.org.uk) and the COMPARE study (www.comparestudy.org.uk), conceived by the University of Cambridge and NHS Blood and Transplant (NHSBT) and managed by the University, indicated that research needed to be conducted on the optimal method of haemoglobin screening. As a result, NHSBT updated training for blood donor centre staff and implemented a new screening process throughout 2018. There are now fewer inappropriate bleeds, leading to increased donor welfare.
URL https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/7847/interval-and-compare-implications-fo...
 
Description COMPARE study
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact The COMPARE study provided NHS Blood and Transplant with the first evidence from a randomised trial (of 30,000 blood donors) as to the most effective way to measure haemoglobin (Hb) levels in blood donors and the effects on the health service and quality of life/health of blood donors of the different methods of Hb measurement and the consequential levels of incorrect bleeding or deferral.
 
Description Chair and organise the annual NHS Blood and Transplant 'Blood Donation Research Horizon Scanning Meeting' (Emanuele Di Angelantonio)
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact This meeting brings together NHS Blood and Transplant senior leadership and academics to discuss new scientific and clinical developments that have potential impact on the national blood donation service.
 
Description Citation of published protocol manuscript
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in clinical reviews
 
Description Citation of published protocol manuscript
Geographic Reach Multiple continents/international 
Policy Influence Type Citation in other policy documents
Impact We have influenced international cardiovascular guidelines through evaluation of the incremental value of assessing established and emerging risk factors for risk assessment, including inflammation biomarkers (NEJM 2012), lipids and lipoproteins (JAMA 2012, Lancet 2010), adiposity measures (Lancet 2011), and carotid ultrasound (Lancet 2012).
 
Description Development of CVD-WHO risk prediction algorithm (Emanuele Di Angelantonio)
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
Impact Membership of the 'World Health Organisation Risk Chart Working Group' and participation in developing an algorithm, for use in a practicable risk model, for cardiovascular disease, which can be re-calibrated to WHO regions/countries.
URL https://www.who.int/cardiovascular_diseases/guidelines/Chart_predictions/en/
 
Description ERFC - influenced training of practioners or researchers
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Description ERFC - major lipids
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
Impact The ERFC paper on major lipids has been cited in the 2011 ESC / EAS Guidelines for the management of dyslipidaemias, in the 2012 ESC Guidelines, the 2011 American Association of Clinical Endocrinologists Medical Guidelines, and the 2011 AHA Statement on Triglycerides and cardiovascular disease. The ERFC publication on the causal relevance of triglyceride-related pathways to coronary disease has been cited in the following guidelines to support the rationale for diagnosis and treatment of hypertriglyceridaemia: the 2012 Endocrine Society Clinical Practice Guideline, the 2011 ESC / EAS Guidelines for the management of dyslipidaemias, and the 2011 AHA Statement on Triglycerides and cardiovascular disease.
 
Description Helped to define genetic and biological determinants of lipid and inflammatory related markers
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Description High-level engagement with industry, exemplified by recent global board meetings with Takeda, Sanofi, Pfizer, Merck and Novartis
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description INTERVAL study
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
Impact The INTERVAL study provided NHS Blood and Transplant with the first data from a randomised trial of the effects of different blood donation intervals. The quantitative data produced from INTERVAL (and published in The Lancet) include data on the amount of blood collected from donors and the health and well being of blood donors and will inform NHSBT policy on blood donation strategies and policy.
 
Description LpPLA2 Studies Collaboration
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Member (and NHSBT representative) of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative (Emanuele Di Angelantonio)
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
Impact This is an international research organisation that works to explore ways to improve transfusion-related services through standardisation of analytic techniques, development of new procedures, systematic review of evidence, and execution of clinical and laboratory studies.
 
Description Member of the NHS Blood and Transplant National Research and Development Committee (Emanuele Di Angelantonio)
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact This committee approves the Research and Development programme, evaluates its delivery, and makes decisions on allocation of research and development funds, thus impacting the effectiveness of NHSBT.
 
Description Member of the NHSBT Clinical Trial Unit Steering Committee (Emanuele Di Angelantonio)
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
 
Description Member of the National NHS Blood and Transplant Blood Donation Research Strategy Group (Emanuele Di Angelantonio)
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact The objective of this group is to ensure the alignment of operational requirements and research activities in the area of blood donor health, welfare, attitude and behaviour, hence contributing to shaping the research strategy.
 
Description Member of the UK Blood Services Standing Advisory Committee on the Care and Selection of Donors (Emanuele Di Angelantonio)
Geographic Reach National 
Policy Influence Type Participation in a advisory committee
Impact This committee advises the UK Blood Services on all matters related to the care and selection of whole blood and component donors and has responsibility for relevant chapters in the Guidelines for the Blood Transfusion Services in the United Kingdom (the Red Book) and for the Whole Blood and Components Donor Selection Guidelines.
 
Description Successfully embedded research protocols within routine framework of National Blood Service
Geographic Reach National 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Training in the analysis of individual participant data from multiple studies
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Description Translational research tools in the analysis of individual participant data from multiple studies
Geographic Reach Multiple continents/international 
Policy Influence Type Participation in a advisory committee
 
Description Academic Alliance Astrazeneca uk limited centre for genomics research
Amount £480,000 (GBP)
Funding ID RG90583 
Organisation AstraZeneca 
Sector Private
Country United Kingdom
Start 08/2017 
End 08/2022
 
Description Association between personal exposure to air pollution and adverse health consequences in South
Amount £15,000 (GBP)
Funding ID RG85685 
Organisation Engineering and Physical Sciences Research Council (EPSRC) 
Sector Academic/University
Country United Kingdom
Start 12/2016 
End 03/2017
 
Description BHF CoE funding for James Peters
Amount £84,915 (GBP)
Funding ID RG68639 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 11/2016 
End 11/2017
 
Description BHF CoE funding for Jonathan Evans
Amount £54,676 (GBP)
Funding ID RG68639 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 08/2017
 
Description BHF CoE funding for Lisa Schmunk
Amount £115,759 (GBP)
Funding ID RG68639 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2016 
End 03/2019
 
Description BHF CoE funding for Parsa Akbari
Amount £115,759 (GBP)
Funding ID RG68639 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 10/2016 
End 09/2019
 
Description BHF, Centre of Excellence - Pump Priming (A Butterworth)
Amount £50,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2015 
End 12/2015
 
Description BHF, Centre of Excellence - Pump Priming (A Wood)
Amount £49,813 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2014 
End 03/2019
 
Description BHF, Centre of Excellence - Pump Priming (D Freitag)
Amount £47,443 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 04/2014 
End 03/2019
 
Description BHF, Centre of Excellence - Pump Priming (D Paul)
Amount £45,000 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2016 
End 12/2017
 
Description BHF, Centre of Excellence - Pump Priming (E Di Angelantonio)
Amount £49,050 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 08/2015 
End 07/2016
 
Description BHF, Centre of Excellence - Pump Priming (E Harshfield)
Amount £49,950 (GBP)
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 05/2015 
End 04/2016
 
Description BHF/Turing Cardiovascular Data Science Awards - Astle
Amount £79,671 (GBP)
Funding ID BDCSA-100024 
Organisation Alan Turing Institute 
Sector Academic/University
Country Unknown
Start 02/2019 
End 07/2020
 
Description BHF/Turing Cardiovascular Data Science Awards - Wood
Amount £91,414 (GBP)
Funding ID BDCSA-100005 
Organisation Alan Turing Institute 
Sector Academic/University
Country Unknown
Start 04/2019 
End 03/2020
 
Description Biogen
Amount £140,000 (GBP)
Organisation Biogen Idec 
Sector Private
Country United States
Start 06/2015 
End 06/2016
 
Description Biogen
Amount £622,283 (GBP)
Organisation Biogen 
Sector Public
Country United Kingdom
Start 01/2017 
End 12/2019
 
Description Biomedical Research Centre grant - Cardiovascular Theme
Amount £463,767 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2012 
End 03/2017
 
Description Biomedical Research Centre grant - Population Science Theme
Amount £1,365,496 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2012 
End 03/2017
 
Description Blood Transplant Research Unit (NIHR - BTRU)
Amount £4,099,619 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 10/2015 
End 09/2020
 
Description British Heart Foundation for Philippe Ghilcrist
Amount £93,850 (GBP)
Funding ID RG68639 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2017 
End 03/2019
 
Description Cambridge Biomedical Research Centre
Amount £114,000,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2017 
End 03/2022
 
Description Cambridge alliance to protect Bangladesh from long0term environmental hazards
Amount £7,946,901 (GBP)
Funding ID MR/P02811X/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2017 
End 12/2021
 
Description ECH2020 Societal Challenge - TRANSPOSE
Amount € 549,478 (EUR)
Funding ID 738145 
Organisation European Commission 
Department Consumer, Health and Food Executive Agency
Sector Public
Country Luxembourg
Start 09/2017 
End 02/2020
 
Description HDRUK
Amount £30,000,000 (GBP)
Organisation Health Data Research UK 
Start 04/2018 
 
Description IMI2 - Big Data for better Hearts
Amount £343,723 (GBP)
Funding ID RG87033 
Organisation European Commission 
Department Innovative Medicines Initiative (IMI)
Sector Multiple
Country European Union (EU)
Start 06/2017 
End 05/2021
 
Description Improving Donor Health (NHSBT)
Amount £299,000 (GBP)
Funding ID WP13-02 
Organisation NHS England 
Sector Public
Country United Kingdom
Start 03/2014 
End 03/2016
 
Description Industrial Strategy PhD Studentship MRC DTP 2018 - Loic Lannelongue
Amount £84,680 (GBP)
Funding ID MR/N013433/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 03/2022
 
Description Industrial Strategy PhD Studentship MRC DTP 2018 - Tao Jiang
Amount £84,680 (GBP)
Funding ID MR/S502443/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 10/2018 
End 03/2022
 
Description Isaac Newton Trust / Wellcome Trust ISSF / University of Cambridge Joint Research Grant Scheme
Amount £80,000 (GBP)
Organisation Wellcome Trust 
Sector Charity/Non Profit
Country United Kingdom
Start 01/2016 
 
Description NIHR Senior Investigator
Amount £45,000 (GBP)
Funding ID NF-SI-0617-10113 
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start 04/2018 
End 03/2021
 
Description NIHR Senior Investigator Award
Amount £45,000 (GBP)
Organisation National Institute for Health Research 
Sector Public
Country United Kingdom
Start  
 
Description Programme Grant
Amount £2,498,808 (GBP)
Funding ID RG/18/13/33946 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 12/2018 
End 12/2023
 
Description RCUK Innovation / Rutherford Fund Fellowships
Amount £451,154 (GBP)
Funding ID MR/S004068/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 04/2018 
End 03/2021
 
Description RCUK Innovation / Rutherford Fund Fellowships
Amount £328,721 (GBP)
Funding ID MR/S003746/1 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 02/2018 
End 02/2021
 
Description Support to enhance phenotyping in the NIHR/NHSBT INTERVAL Bioresource
Amount £53,556 (GBP)
Funding ID RG86292 
Organisation Cambridge University Hospitals NHS Foundation Trust 
Sector Public
Country United Kingdom
Start 04/2016 
End 03/2017
 
Description THE MALAYSIAN ACUTE VASCULAR EVENTS RISK (MAVERIK) STUDY
Amount £400,000 (GBP)
Funding ID RG85814 
Organisation Medical Research Council (MRC) 
Sector Academic/University
Country United Kingdom
Start 01/2017 
End 12/2018
 
Description USING GENOMICS TO ANTICIPATE CONSEQUENCES OF LIPOPROTEIN(A)-LOWERING: IMPLICATIONS FOR PHASE3 CARDIOVASCULAR OUTCOMES TRIALS
Amount £344,886 (GBP)
Funding ID RG91975 
Organisation Novartis 
Department Novartis Pharmaceuticals UK Ltd
Sector Private
Country United Kingdom
Start 09/2017 
End 08/2018
 
Description Using Genetics to explore the pathophysiology of Cerebral Small Vessel Disease
Amount £94,369 (GBP)
Funding ID RG83983 
Organisation British Heart Foundation (BHF) 
Sector Charity/Non Profit
Country United Kingdom
Start 09/2016 
End 08/2021
 
Title BELIEVE 
Description Collection of samples from the BangladEsh Longitudinal Investigation of Emerging Vascular Events (BELIEVE) study: The study, in collaboration with National Heart Foundation in Bangladesh, aims to recruit up to 50,000 community-based individuals (age >5 years) from households in Bangladesh. The study population will be recruited through household survey (initially in urban areas of Capital Dhaka, and then from a semi-rural Sylhet region) to ensure maximum and generalizable participation, particularly from individuals with shared environmental and genetic background. The key objectives of the BELIEVE prospective cohort study are to create a re-callable population and bio-resource involving a general South Asian population to: (1) enable genetic discovery using diverse phenotypes (particularly those related to nutrition such as anaemia, infection, or environment-related aspects such as air and toxic metal pollution), causal evaluation and functional genomics; (2) assess reliably the roles of established and unique locally-relevant risk factors on incident NCDs such as cardiovascular, cancer, diabetes and kidney diseases (ascertained by clinical records and standardised validation); (3) help study discrepant risk factor patterns unique to this population (eg, unusually high tobacco usage, lowest average body mass index, highest physical inactivity rates) over time, in various age groups as a life-course approach; and their heritability; and (4) create a well-characterised population base to set-up innovative and cost-effective behaviour modification and pharmaceutical interventions, suitable from a South-Asian context. 
Type Of Material Biological samples 
Year Produced 2017 
Provided To Others? No  
Impact None yet, samples and data still being collected and analysed. 
 
Title BRAVE 
Description Collection of biological samples from Bangladesh Risk of Acute Vascular Events (BRAVE) study: Commenced in 2011, BRAVE is being implemented locally in collaboration with National Institute of Cardiovascular Disease Bangladesh, and Chronic Non-Communicable Diseases Unit of icddr,b. As of 2015, BRAVE has already recruited over 6000 first-ever myocardial infarction cases and 6000 healthy controls from capital Dhaka city. Information and biological specimen routinely collected include data using a 400-item questionnaire, physical measurements, blood, toe-nail and extracted DNA samples from all participants. The main objectives of this study are to: •assess the role of potential CVD risk factors (highly prevalent in Bangladeshis) that are yet to be characterized in detail, including: long-term arsenic and other toxic metal contaminations (both separately and in combination), indigenous tobacco consumption; sub-optimal nutrition and genetic variation. •estimate the impact of modifiable conventional vascular risk factors (eg, smoking, history of hypertension, diabetes, physical inactivity, obesity, lipid fractions) on vascular disease in Bangladesh. •evaluate the important local lifestyle, socioeconomic and nutritional exposures on CVD risk, such as diet (eg, local intake patterns of various oil, spices, dairy and fish) and different socio-economic groups; •collect reliable information on knowledge, perception and practice to prevent CVD among participants in order to better understand public health awareness of vascular disease in Bangladesh; and •collect detailed information on the economic burden of CVD events in Bangladesh better understand health economic impact of vascular disease in Bangladesh. 
Type Of Material Biological samples 
Year Produced 2015 
Provided To Others? Yes  
Impact Publications 
 
Title COMPARE 
Description COMPARE is a study of 30,000 English blood donors set up to determine for NHS Blood and Transplant the most effective way of measuring haemaglobin levels in blood donors. Additionally, participants in the study have consented to have the blood samples used in research and data from genetic and biomarker assays and through linkage with electronic health records will be used across a range of research projects. 
Type Of Material Biological samples 
Year Produced 2017 
Provided To Others? Yes  
Impact No impact yet. 
URL http://www.comparestudy.org.uk/about-the-study/
 
Title EPIC-Heart Assays 
Description Assays have now been completed in all EPIC-Heart participants on the following phenotypes: - 22 clinical chemistry biomarkers - 210,000 genetic variants - a further 450,000 genetic variants - a panel of 37 fatty acids Assays are near completion in these participants for vitamins C and D, a panel of 6 carotenoids and telomere length. These assays are also being extended to stroke cases identified under the FP7 funded project, EPIC-CVD, adding further value to the EPIC-Heart project. 
Type Of Material Physiological assessment or outcome measure 
Year Produced 2012 
Provided To Others? Yes  
Impact N/A 
 
Title Emerging Risk Factors Collaboration database 
Description A database has been created of harmonised individual participant data records from over 2 million individuals 
Type Of Material Improvements to research infrastructure 
Provided To Others? No  
Impact Published article PMID: 19903920 
URL http://europepmc.org/abstract/MED/19903920
 
Title Emerging Risk Factors Collaboration statistical methods 
Description Several novel statistical methods have been developed to enable maximal exploitation of the Emerging Risk Factors Collaboration database. 
Type Of Material Improvements to research infrastructure 
Provided To Others? No  
Impact Publication of article PMID: 19903920 
URL http://europepmc.org/abstract/MED/19903920
 
Title INTERVAL Bioresource 
Description INTERVAL is a randomised controlled trial in up to 50,000 whole-blood donors recruited at 25 locations across England. Participants are involved in a two-year intervention during which they are invited to give blood either at usual donation intervals or more often. The primary aim of the intervention is to establish whether donors can safely and acceptably give blood more often than is now collected by NHS Blood and Transplant. A further aim of INTERVAL is to create a national epidemiological bioresource, including a recall-by-genotype (phenotype) resource, which will enable detailed study of the health of blood donors and broader public health and biomedical issues. Participant recruitment commenced in June 2012. Our target of 50,000 study participants was reached two years later, in June 2014. Participants have consented to: use of their data and biological samples for a wide range of analyses, invitation to further biomedical studies, and long-term linkage to e-health records. Funding that has been awarded from NHSBT and NIHR will allow the study of the following factors in 50,000 participants i) extended haematological profile (>200 parameters) ii) lifestyle profiling, including assessment of smoking, alcohol consumption, dietary intake, and, in large subsets, monitoring of physical activity through the use of worn accelerometry devices; (iii) cognitive function traits related to different domains of mental function and well-being; and (iv) linkage with e-health records, eg, various morbidity registers, hospital discharge records (v) a novel gene array containing 850,000 single nucleotide variants (SNVs), which includes many functional SNVs and a GWAS scaffold to deliver imputation of ~20 million variants; (vi) ~200 candidate biomarkers related to haematological traits and other pathways for a wide range of disease processes (eg, liver and renal function; autoimmunity; hormonal status). 
Type Of Material Biological samples 
Year Produced 2014 
Provided To Others? Yes  
Impact Serum samples collected during the study have been used to measure the levels of ferritin in participants. DNA has been used in a genome-wide association study of haemoglobin concentration and related parameters, and genotyping of the HFE gene. 
 
Title Methods 
Description To allow the assessment of risk prediction in a multi-centre case-cohort study, novel statistical methods have been developed at the EPIC-Heart Coordinating Centre 
Type Of Material Improvements to research infrastructure 
Year Produced 2011 
Provided To Others? Yes  
Impact A Publication: "Derivation and assessment of risk prediction models using case-cohort data". Sanderson J, Thompson SG, White IR, Aspelund T, Pennells L. BMC Med Res Methodol. 2013 Sep 13;13(1):113 
 
Title PROMIS 
Description Collection of samples from The Pakistan Risk of Myocardial Infarction Study (PROMIS): 35,000 participants have been recruited for this study aged 30-80 years (both male and female) with a first-ever confirmed myocardial infarction (MI) and "frequency-matched" controls (on age and sex) free from cardiovascular or other chronic diseases. Information collected on each participant includes a detailed questionnaire (including extensive information on lifestyle and dietary habits tailored to local dietary patterns), blood samples (including serum, plasma and whole blood) and DNA extracted from white blood cells. Samples are transported to the core laboratory at the Department of Public Health and Primary Care, University of Cambridge, for long-term storage and subsequent genetic and biochemical analyses. PROMIS will help to identify and understand the separate and combined influences of genetic and major lifestyle factors on the risk of MI, and to help elucidate intermediate causal pathways. Investigations underway in the available cases and controls already collected include assessment of candidate gene, biochemical, dietary and lifestyle influences as well as genome wide association studies. We are exploring collection of more detailed information in a sizeable subset of participants to enable more detailed investigations, such as the establishment of cell-lines and studies of gene expression (using RNA samples from monocytes, lipid biopsies and other sources). 
Type Of Material Biological samples 
Year Produced 2012 
Provided To Others? Yes  
Impact Publications 
 
Title Quantifying net benefits 
Description A framework for quantifying net benefits of alternative prognostic models 
Type Of Material Improvements to research infrastructure 
Provided To Others? No  
Impact Publication 21905066 
 
Title Statistical programs made freely available to researchers 
Description Bespoke statistical programs for the meta-analysis of individual participant data have been made freely available to researchers via the ERFC website 
Type Of Material Improvements to research infrastructure 
Year Produced 2009 
Provided To Others? Yes  
Impact N/A 
URL http://www.phpc.cam.ac.uk/ceu/research/erfc/stata/
 
Title The Lp-PLA2 Studies Collaboration database 
Description A database has been created of harmonised individual participant data records from over 110,000 individuals 
Type Of Material Improvements to research infrastructure 
Provided To Others? No  
Impact n/a 
 
Title BELIEVE Urban 
Description Collection of data from the BangladEsh Longitudinal Investigation of Emerging Vascular Events in urban setting (BELIEVE-Urban) study: The study, in collaboration with National Heart Foundation in Bangladesh, aims to recruit up to 80,000 community-based individuals (age >5 years) from households in Bangladesh. The study population will be recruited through household survey (initially in urban areas of Capital Dhaka, and then from a semi-rural Sylhet region) to ensure maximum and generalizable participation, particularly from individuals with shared environmental and genetic background. The key objectives of the BELIEVE Urban prospective cohort study are to create a re-callable population and bio-resource involving a general South Asian population to: (1) enable genetic discovery using diverse phenotypes (particularly those related to nutrition such as anaemia, infection, or environment-related aspects such as air and toxic metal pollution), causal evaluation and functional genomics; (2) assess reliably the roles of established and unique locally-relevant risk factors on incident NCDs such as cardiovascular, cancer, diabetes and kidney diseases (ascertained by clinical records and standardised validation); (3) help study discrepant risk factor patterns unique to this population (eg, unusually high tobacco usage, lowest average body mass index, highest physical inactivity rates) over time, in various age groups as a life-course approach; and their heritability; and (4) create a well-characterised population base to set-up innovative and cost-effective behaviour modification and pharmaceutical interventions, suitable from a South-Asian context. 
Type Of Material Database/Collection of data 
Year Produced 2017 
Provided To Others? No  
Impact None yet, samples and data still being collected and analysed. 
URL http://www.capable-bangladesh.org/cohorts/believe-urban/
 
Title BRAVE 
Description Collection of data from Bangladesh Risk of Acute Vascular Events (BRAVE) study: Commenced in 2011, BRAVE is being implemented locally in collaboration with National Institute of Cardiovascular Disease Bangladesh, and Chronic Non-Communicable Diseases Unit of icddr,b. As of 2015, BRAVE has already recruited over 6000 first-ever myocardial infarction cases and 6000 healthy controls from capital Dhaka city. Information and biological specimen routinely collected include data using a 400-item questionnaire, physical measurements, blood, toe-nail and extracted DNA samples from all participants. The main objectives of this study are to: •assess the role of potential CVD risk factors (highly prevalent in Bangladeshis) that are yet to be characterized in detail, including: long-term arsenic and other toxic metal contaminations (both separately and in combination), indigenous tobacco consumption; sub-optimal nutrition and genetic variation. •estimate the impact of modifiable conventional vascular risk factors (eg, smoking, history of hypertension, diabetes, physical inactivity, obesity, lipid fractions) on vascular disease in Bangladesh. •evaluate the important local lifestyle, socioeconomic and nutritional exposures on CVD risk, such as diet (eg, local intake patterns of various oil, spices, dairy and fish) and different socio-economic groups; •collect reliable information on knowledge, perception and practice to prevent CVD among participants in order to better understand public health awareness of vascular disease in Bangladesh; and •collect detailed information on the economic burden of CVD events in Bangladesh better understand health economic impact of vascular disease in Bangladesh. 
Type Of Material Database/Collection of data 
Year Produced 2015 
Provided To Others? Yes  
Impact Publications 
 
Title CARDIoGRAMplusC4D consortium 
Description Genetic consortium 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 
 
Title COMPARE 
Description COMPARE is a study of 30,000 English blood donors set up to determine for NHS Blood and Transplant the most effective way of measuring haemaglobin levels in blood donors. Additionally, participants in the study have consented to have the blood samples used in research and data from genetic and biomarker assays and through linkage with electronic health records will be used across a range of research projects. 
Type Of Material Database/Collection of data 
Year Produced 2017 
Provided To Others? Yes  
Impact No impact yet. 
URL http://www.comparestudy.org.uk/about-the-study/
 
Title EPIC-CVD database 
Description The EPIC-Heart phenotype database is being expanded to stroke outcomes (~9000 incident cases), rather than just coronary disease, adding further value to the initial investment 
Type Of Material Database/Collection of data 
Year Produced 2014 
Provided To Others? Yes  
Impact N/A 
 
Title Emerging Risk Factors Collaboration Database 
Description A database has been created of harmonised individual participant data records from over 2 million individuals 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact Published article PMID: 19903920 
URL http://europepmc.org/abstract/MED/19903920
 
Title Exome Chip Consortium 
Description Exome chip consortium 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact N/A 
 
Title INTERVAL Bioresource 
Description INTERVAL is a randomised controlled trial in up to 50,000 whole-blood donors recruited at 25 locations across England. Participants are involved in a two-year intervention during which they are invited to give blood either at usual donation intervals or more often. The primary aim of the intervention is to establish whether donors can safely and acceptably give blood more often than is now collected by NHS Blood and Transplant. A further aim of INTERVAL is to create a national epidemiological bioresource, including a recall-by-genotype (phenotype) resource, which will enable detailed study of the health of blood donors and broader public health and biomedical issues. Participant recruitment commenced in June 2012. Our target of 50,000 study participants was reached two years later, in June 2014. Participants have consented to: use of their data and biological samples for a wide range of analyses, invitation to further biomedical studies, and long-term linkage to e-health records. Funding that has been awarded from NHSBT and NIHR will allow the study of the following factors in 50,000 participants i) extended haematological profile (>200 parameters) ii) lifestyle profiling, including assessment of smoking, alcohol consumption, dietary intake, and, in large subsets, monitoring of physical activity through the use of worn accelerometry devices; (iii) cognitive function traits related to different domains of mental function and well-being; and (iv) linkage with e-health records, eg, various morbidity registers, hospital discharge records (v) a novel gene array containing 850,000 single nucleotide variants (SNVs), which includes many functional SNVs and a GWAS scaffold to deliver imputation of ~20 million variants; (vi) ~200 candidate biomarkers related to haematological traits and other pathways for a wide range of disease processes (eg, liver and renal function; autoimmunity; hormonal status). 
Type Of Material Database/Collection of data 
Year Produced 2014 
Provided To Others? Yes  
Impact Further collaboration, most notably with the Wellcome Trust Sanger Institute 
URL http://www.intervalstudy.org.uk/
 
Title Large-scale Research Database Established 
Description Dataset from >130 studies with over 2.3M individuals and 100,000 cases of cardiovascular disease with information on conventional risk factors for CVD and other circulating biomarkers and lifestyle factors. 
Type Of Material Database/Collection of data 
Year Produced 2009 
Provided To Others? Yes  
Impact N/A 
 
Title MAVERIK 
Description MAVERIK is a case-control study of acute vascular events in Malaysia. 2,500 cases and 2,500 control participants are being collected from hospitals across Malaysia. Participants answer questionnaires and provide blood samples which will help the understanding a cardiovascular events, including risk factors specific to Malaysia. 
Type Of Material Database/Collection of data 
Year Produced 2018 
Provided To Others? Yes  
Impact Publication. 
 
Title Mendelian Randomisation Method 
Description Dataset of over 40,000 cases of CHD in over 180,000 participants from 47 studies with data on CRP genetic variants, circulating CRP and other biomarkers. Statistical methods for further developing the methodology for Mendelian randomization analyses. 
Type Of Material Data analysis technique 
Year Produced 2014 
Provided To Others? Yes  
Impact N/A 
 
Title Metabochip Consortium 
Description Metabochip Consortium database 
Type Of Material Database/Collection of data 
Provided To Others? No  
Impact N/A 
 
Title PROMIS 
Description Collection of data from The Pakistan Risk of Myocardial Infarction Study (PROMIS): 35,000 participants have been recruited for this study aged 30-80 years (both male and female) with a first-ever confirmed myocardial infarction (MI) and "frequency-matched" controls (on age and sex) free from cardiovascular or other chronic diseases. Information collected on each participant includes a detailed questionnaire (including extensive information on lifestyle and dietary habits tailored to local dietary patterns), blood samples (including serum, plasma and whole blood) and DNA extracted from white blood cells. Samples are transported to the core laboratory at the Department of Public Health and Primary Care, University of Cambridge, for long-term storage and subsequent genetic and biochemical analyses. PROMIS will help to identify and understand the separate and combined influences of genetic and major lifestyle factors on the risk of MI, and to help elucidate intermediate causal pathways. Investigations underway in the available cases and controls already collected include assessment of candidate gene, biochemical, dietary and lifestyle influences as well as genome wide association studies. We are exploring collection of more detailed information in a sizeable subset of participants to enable more detailed investigations, such as the establishment of cell-lines and studies of gene expression (using RNA samples from monocytes, lipid biopsies and other sources). 
Type Of Material Database/Collection of data 
Year Produced 2010 
Provided To Others? Yes  
Impact Publications 
 
Title Phenoscanner 
Description Mendelian Randomisation (MR) Catalogue is a curated database of publicly available results from large-scale genetic association studies. This tool aims to facilitate "phoneme scans", the cross-referencing of genetic variants with many phenotypes, to help aid understanding of disease pathways and biology as well as inform MR studies. The catalogue currently contains over 300 million association results and over 10 million unique genetic variants, mostly single nucleotide polymorphisms. It is accompanied by a web-based tool that queries the database for associations with user-specified variants, providing results aligned according to the alleles of each input variant. The tool provides the option of searching for trait associations with proxies of the input variants, calculated using the European samples from 1000 Genomes phase 3. 
Type Of Material Database/Collection of data 
Year Produced 2016 
Provided To Others? Yes  
Impact MR Catalogue has been used extensively within the Cardiovascular Epidemiology Unit, University of Cambridge, and has been used in a few high profile papers currently under review. We recently released MR Catalogue to the wider scientific community and we have had over 1,000 usages of the website already. We anticipate that this tool will be widely used within the genetics community. 
URL http://www.phenoscanner.medschl.cam.ac.uk/phenoscanner
 
Title Statistical Methods and Database 
Description Dataset from >130 studies with over 2.3M individuals and 100,000 cases of cardiovascular disease with information on conventional risk factors for CVD and other circulating biomarkers and lifestyle factors. 
Type Of Material Database/Collection of data 
Year Produced 2009 
Provided To Others? Yes  
Impact N/A 
 
Title Statistical methodology (optimistic prediction) 
Description Correcting for Optimistic Prediction in Small Data Sets 
Type Of Material Data analysis technique 
Year Produced 2014 
Provided To Others? Yes  
Impact N/A 
 
Description AstraZeneca 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution The collaboration with AstraZeneca has two parts: 1) Using genomic and molecular information in the INTERVAL study to inform AstraZeneca's therapeutic target prioritisation. We aim: a) To systematically mine CEU's datasets for association signals in or near genes relevant to AZ targets to enable the creation of genetic scores that mimic therapeutic intervention b) To validate informative scores by identifying associations with relevant "positive control" outcomes, such as diseases, molecular biomarkers or traits. c) To assess the association of informative scores on a wide range of molecular and clinical outcomes to inform drug efficacy, on-target safety and/or alternative indications. 2) Whole blood RNA sequencing in the INTERVAL study: we will validate whole blood mRNA sequencing from INTERVAL donors as a robust and scalable 'omics layer to add to the detailed genomic and molecular phenotyping that exists in these participants.
Collaborator Contribution Funding support of £480,000 and provided a list of high-priority therapeutic targets, with primary indications of interest, and supporting information across a number of domains of biological and clinical science.
Impact Presented results at the AstraZeneca Centre for Genomics Research Annual Collaborators in July 2018. IGMM Seminar University of Edinburgh (Adam Butterworth)
Start Year 2017
 
Description BRAVE 
Organisation International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Country Bangladesh 
Sector Charity/Non Profit 
PI Contribution Funding, protocol design and implementation support; analysis of data and publication manuscript preparation. Scientific leadership.
Collaborator Contribution Conduct of the protocol, use of resources and sample/data transport
Impact Publications
Start Year 2010
 
Description Biogen 
Organisation Biogen Idec
Country United States 
Sector Private 
PI Contribution Scientific expertise; data analysis; provision of samples; development of statistical methodologies; access to dense genotypic and phenotpyic datasets.
Collaborator Contribution Financial and scientific input.
Impact No outcomes yet.
Start Year 2017
 
Description CAPABLE - BSMMU 
Organisation Bangabandhu Sheikh Mujib Medical University
Country Bangladesh 
Sector Academic/University 
PI Contribution Intellectual input and scientific direction/coordination to help set up a research cohort to better understand disease and environmental risks in Bangladesh. Coordinating centre for the CAPABLE programme under which this collaboration sits.
Collaborator Contribution Intellectual input and scientific direction/coordination to help set up a research cohort to better understand disease and environmental risks in Bangladesh. Provision of staff, resources, space.
Impact No outputs yet.
Start Year 2017
 
Description CAPABLE - IEDCR 
Organisation Institute of Epidemiology Disease Control And Research
PI Contribution Intellectual input to the research into environmental and lifestyle risk factors in Bangladesh with respect to non-communicable diseases, as well as the planning and coordination of capacity building and training in the programme. Coordinating centre responsible for the CAPABLE consortium under which this collaboration sits.
Collaborator Contribution Intellectual input to the research into environmental and lifestyle risk factors in Bangladesh with respect to non-communicable diseases, as well as the planning and coordination of capacity building and training in the programme. Provision of space and resources for capacity building elements of the programme.
Impact Not outputs yet.
Start Year 2017
 
Description CAPABLE-University College London 
Organisation University College London
Department Institute For Global Health
Country United Kingdom 
Sector Academic/University 
PI Contribution Intellectual input and scientific direction/coordination to help set up a work stream on social determinants and better understand disease and environmental risks in Bangladesh.
Collaborator Contribution Intellectual input and scientific direction/coordination to help set up a work stream on social determinants, policy and gender studies to better understand disease and environmental risks in Bangladesh. Supervision of fellows, capacity building.
Impact No outcomes yet
Start Year 2017
 
Description CAPABLE-University of Aberdeen 
Organisation University of Aberdeen
Country United Kingdom 
Sector Academic/University 
PI Contribution Intellectual input and scientific direction/coordination for studying arsenic and other environmental toxic metals. Coordinating centre for analytical analyses in biological and non-biological samples.
Collaborator Contribution Intellectual input and scientific direction/coordination to better understand disease and environmental risks in Bangladesh. Provision of staff, resources, space, capacity building, development of novel analytical methods to study the concentration of toxic metals in biological and non-biological samples.
Impact No outputs yet
Start Year 2017
 
Description CARDIoGRAMplusC4D consortium 
Organisation Chinese Academy of Medical Sciences (CAMS)
Country China 
Sector Academic/University 
PI Contribution Coordinating centre
Collaborator Contribution contribution of data and analyses
Impact Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction - PMCID: PMC3612051
Start Year 2010
 
Description CARDIoGRAMplusC4D consortium 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution Coordinating centre
Collaborator Contribution contribution of data and analyses
Impact Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction - PMCID: PMC3612051
Start Year 2010
 
Description CARDIoGRAMplusC4D consortium 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution Coordinating centre
Collaborator Contribution contribution of data and analyses
Impact Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction - PMCID: PMC3612051
Start Year 2010
 
Description CARDIoGRAMplusC4D consortium 
Organisation Queen Mary University of London
Department Barts and The London School of Medicine and Dentistry
Country United Kingdom 
Sector Academic/University 
PI Contribution Coordinating centre
Collaborator Contribution contribution of data and analyses
Impact Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction - PMCID: PMC3612051
Start Year 2010
 
Description CARDIoGRAMplusC4D consortium 
Organisation University of Leicester
Country United Kingdom 
Sector Academic/University 
PI Contribution Coordinating centre
Collaborator Contribution contribution of data and analyses
Impact Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction - PMCID: PMC3612051
Start Year 2010
 
Description CARDIoGRAMplusC4D consortium 
Organisation University of Lubeck
Country Germany 
Sector Academic/University 
PI Contribution Coordinating centre
Collaborator Contribution contribution of data and analyses
Impact Large-scale association analysis identifies new risk loci for coronary artery disease - PMCID: PMC3679547 Genetic Variants from Lipid-Related Pathways and Risk for Incident Myocardial Infarction - PMCID: PMC3612051
Start Year 2010
 
Description Exome Chip Consortium 
Organisation Harvard University
Department Harvard T.H. Chan School of Public Health
Country United States 
Sector Academic/University 
PI Contribution coordinating centre
Collaborator Contribution funding, contribution of data and analyses
Impact N/A
Start Year 2012
 
Description Exome Chip Consortium 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution coordinating centre
Collaborator Contribution funding, contribution of data and analyses
Impact N/A
Start Year 2012
 
Description Exome Chip Consortium 
Organisation Merck
Country Germany 
Sector Private 
PI Contribution coordinating centre
Collaborator Contribution funding, contribution of data and analyses
Impact N/A
Start Year 2012
 
Description Exome Chip Consortium 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution coordinating centre
Collaborator Contribution funding, contribution of data and analyses
Impact N/A
Start Year 2012
 
Description Exome Chip Consortium 
Organisation Pfizer Global R & D
Country United States 
Sector Private 
PI Contribution coordinating centre
Collaborator Contribution funding, contribution of data and analyses
Impact N/A
Start Year 2012
 
Description Exome Chip Consortium 
Organisation Queen Mary University of London
Department Barts and The London School of Medicine and Dentistry
Country United Kingdom 
Sector Academic/University 
PI Contribution coordinating centre
Collaborator Contribution funding, contribution of data and analyses
Impact N/A
Start Year 2012
 
Description Exome Chip Consortium 
Organisation University of Leicester
Country United Kingdom 
Sector Academic/University 
PI Contribution coordinating centre
Collaborator Contribution funding, contribution of data and analyses
Impact N/A
Start Year 2012
 
Description Genetic Association Study of Blood Pressure (BP Exome) 
Organisation Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE)
Country Global 
Sector Academic/University 
PI Contribution CHD Exome+ consortium jointly led this research project and also contributed samples to the discovery meta-analyses.
Collaborator Contribution ExomeBP and GoT2D Consortia contributed samples for the discovery meta-analyses and CHARGE+ consortium contributed replication samples.
Impact Manuscript under consideration at Nature Genetics
Start Year 2014
 
Description Genetic Association Study of Blood Pressure (BP Exome) 
Organisation Go T2D Consortium
Country Unknown 
Sector Learned Society 
PI Contribution CHD Exome+ consortium jointly led this research project and also contributed samples to the discovery meta-analyses.
Collaborator Contribution ExomeBP and GoT2D Consortia contributed samples for the discovery meta-analyses and CHARGE+ consortium contributed replication samples.
Impact Manuscript under consideration at Nature Genetics
Start Year 2014
 
Description Global BMI Mortality Collaboration 
Organisation Harvard University
Department Harvard T.H. Chan School of Public Health
Country United States 
Sector Academic/University 
PI Contribution The Global BMI Mortality Collaboration was established to enable valid estimation of associations of overweight and obesity with all-cause mortality across populations in major global regions. The consortium involves data from large individual prospective studies (defined as =100,000 participants recruited at baseline) or large multi-cohort consortia (defined as involving a total of =100,000 participants recruited at baseline). A pre-specified analysis plan for combining individual-participant data from relevant cohorts was agreed among collaborators.
Collaborator Contribution The Global BMI Mortality Collaboration was established to enable valid estimation of associations of overweight and obesity with all-cause mortality across populations in major global regions. The consortium involves data from large individual prospective studies (defined as =100,000 participants recruited at baseline) or large multi-cohort consortia (defined as involving a total of =100,000 participants recruited at baseline). A pre-specified analysis plan for combining individual-participant data from relevant cohorts was agreed among collaborators.
Impact The Global BMI Mortality Collaboration was established to enable valid estimation of associations of overweight and obesity with all-cause mortality across populations in major global regions. The consortium involves data from large individual prospective studies (defined as =100,000 participants recruited at baseline) or large multi-cohort consortia (defined as involving a total of =100,000 participants recruited at baseline). A pre-specified analysis plan for combining individual-participant data from relevant cohorts was agreed among collaborators.
Start Year 2013
 
Description Global Lipids Genetics Consortium (GLGC) 
Organisation Global Lipids Genetic Consortium (GLGC)
Country United States 
Sector Charity/Non Profit 
PI Contribution CHD Exome+ consortium contributed samples to the discovery meta-analyses.
Collaborator Contribution GLGC Consortium leads this analyses
Impact Manuscript currently being drafted
Start Year 2013
 
Description HbF collaboration with University of Oxford 
Organisation University of Oxford
Department Department of Plant Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of samples; access to genetic databases; scientific input.
Collaborator Contribution Performing HbF assays; scientific input.
Impact No output yet.
Start Year 2016
 
Description IMR Malaysia 
Organisation Ministry of Health Malaysia
Department Institute for Medical Research
Country Malaysia 
Sector Public 
PI Contribution This collaboration led to securing of additional £200000 funding from the Malaysian Academy of Science. We are working closely with the IMR researchers to implement the MAVERIK study.
Collaborator Contribution IMR researchers are contributing to design and implementation of the study.
Impact None so far as the research study is still in progress.
Start Year 2017
 
Description INTERVAL 
Organisation NHS Blood and Transplant (NHSBT)
Country United Kingdom 
Sector Public 
PI Contribution We provide scientific leadership and operational support. We are the academic coordinating centre, running the administration and data management of the trial (including the helpline).
Collaborator Contribution NHSBT provide funding and operational support. The University of Oxford provide scientific leadership and operational support.
Impact INTERVAL is a randomised controlled trial in up to 50,000 whole-blood donors recruited at 25 locations across England. Participants are involved in a two-year intervention during which they are invited to give blood either at usual donation intervals or more often. The primary aim of the intervention is to establish whether donors can safely and acceptably give blood more often than is now collected by NHS Blood and Transplant. A further aim of INTERVAL is to create a national epidemiological bioresource, including a recall-by-genotype (phenotype) resource, which will enable detailed study of the health of blood donors and broader public health and biomedical issues. Participant recruitment commenced in June 2012. Our target of 50,000 study participants was reached two years later, in June 2014. Participants have consented to: use of their data and biological samples for a wide range of analyses, invitation to further biomedical studies, and long-term linkage to e-health records. Funding that has been awarded from NHSBT and NIHR will allow the study of the following factors in 50,000 participants i) extended haematological profile (>200 parameters) ii) lifestyle profiling, including assessment of smoking, alcohol consumption, dietary intake, and, in large subsets, monitoring of physical activity through the use of worn accelerometry devices; (iii) cognitive function traits related to different domains of mental function and well-being; and (iv) linkage with e-health records, eg, various morbidity registers, hospital discharge records (v) a novel gene array containing 850,000 single nucleotide variants (SNVs), which includes many functional SNVs and a GWAS scaffold to deliver imputation of ~20 million variants; (vi) ~200 candidate biomarkers related to haematological traits and other pathways for a wide range of disease processes (eg, liver and renal function; autoimmunity; hormonal status).
Start Year 2012
 
Description INTERVAL 
Organisation University of Oxford
Country United Kingdom 
Sector Academic/University 
PI Contribution We provide scientific leadership and operational support. We are the academic coordinating centre, running the administration and data management of the trial (including the helpline).
Collaborator Contribution NHSBT provide funding and operational support. The University of Oxford provide scientific leadership and operational support.
Impact INTERVAL is a randomised controlled trial in up to 50,000 whole-blood donors recruited at 25 locations across England. Participants are involved in a two-year intervention during which they are invited to give blood either at usual donation intervals or more often. The primary aim of the intervention is to establish whether donors can safely and acceptably give blood more often than is now collected by NHS Blood and Transplant. A further aim of INTERVAL is to create a national epidemiological bioresource, including a recall-by-genotype (phenotype) resource, which will enable detailed study of the health of blood donors and broader public health and biomedical issues. Participant recruitment commenced in June 2012. Our target of 50,000 study participants was reached two years later, in June 2014. Participants have consented to: use of their data and biological samples for a wide range of analyses, invitation to further biomedical studies, and long-term linkage to e-health records. Funding that has been awarded from NHSBT and NIHR will allow the study of the following factors in 50,000 participants i) extended haematological profile (>200 parameters) ii) lifestyle profiling, including assessment of smoking, alcohol consumption, dietary intake, and, in large subsets, monitoring of physical activity through the use of worn accelerometry devices; (iii) cognitive function traits related to different domains of mental function and well-being; and (iv) linkage with e-health records, eg, various morbidity registers, hospital discharge records (v) a novel gene array containing 850,000 single nucleotide variants (SNVs), which includes many functional SNVs and a GWAS scaffold to deliver imputation of ~20 million variants; (vi) ~200 candidate biomarkers related to haematological traits and other pathways for a wide range of disease processes (eg, liver and renal function; autoimmunity; hormonal status).
Start Year 2012
 
Description Lipidomics - MRC-HNR 
Organisation Medical Research Council (MRC)
Department MRC Human Nutrition Research Unit
Country United Kingdom 
Sector Public 
PI Contribution We provided samples from 50,000 participants (whole cohort) from the INTERVAL study for analysis
Collaborator Contribution Analysis of all 50,000 samples in progress - 400 lipid species measured. Assays contributed in kind by MRC-HNR
Impact Data received at regular intervals
Start Year 2015
 
Description MAVERIK 
Organisation IInstitute for Medical Research
Country Malaysia 
Sector Public 
PI Contribution Funding, protocol design and implementation support; analysis of data and publication manuscript preparation. Scientific leadership.
Collaborator Contribution Funding, protocol design and implementation support; recruitment of participants into case/control study.
Impact None yet.
Start Year 2017
 
Description MAVERIK 
Organisation International Medical University
Country Malaysia 
Sector Academic/University 
PI Contribution Funding, protocol design and implementation support; analysis of data and publication manuscript preparation. Scientific leadership.
Collaborator Contribution Funding, protocol design and implementation support; recruitment of participants into case/control study.
Impact None yet.
Start Year 2017
 
Description MAVERIK 
Organisation National Heart Institute
Country Malaysia 
Sector Hospitals 
PI Contribution Funding, protocol design and implementation support; analysis of data and publication manuscript preparation. Scientific leadership.
Collaborator Contribution Funding, protocol design and implementation support; recruitment of participants into case/control study.
Impact None yet.
Start Year 2017
 
Description NIHR BTRU in Donor Health and Genomics 
Organisation NHS Blood and Transplant (NHSBT)
Department National Blood Service
Country United Kingdom 
Sector Public 
PI Contribution The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge is a cross-disciplinary unit established to address major questions about the health of blood donors and produce evidence-based strategies to enhance donor safety and ensure sustainability of blood supply. We are the grant holders and managers of this unit.
Collaborator Contribution The Unit is building and exploiting exceptionally large and detailed "living laboratories" of healthy participants who consent to frequent and active engagement in research studies (eg, recall-by-genotype, periodic re-attendance, wearing of devices, linkage with e-health records). For example, leveraging our strategic relationship with NHSBT, we have commenced linkage of >1M blood donors to e-health records. As a proof-of-concept study, we have already enrolled 50,000 donors into the INTERVAL Study in which we have commenced cohort-wide 15X whole genome sequencing, measured >5000 molecular phenotypes (eg, lipids, metabolites, proteins), conducted an advanced analysis of the cellular composition of the blood, employed accelerometry devices at scale and measured genome-wide genotypes.
Impact The goals of this new Unit are to combine cutting-edge tools from genomics, biology and population health science to address key questions about the aetiology of important disorders (such as the health consequences of iron deficiency), to improve the safety and precision of blood donation, and to build and use major genomic resources that enable the study of important chronic diseases of wider relevance. This unit combined the disciplines of clinical studies, functional genetics, epidemiology and statistics/bioinformatics.
Start Year 2015
 
Description NIHR BTRU in Donor Health and Genomics 
Organisation The Wellcome Trust Sanger Institute
Department Human Complex Traits
Country United Kingdom 
Sector Academic/University 
PI Contribution The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge is a cross-disciplinary unit established to address major questions about the health of blood donors and produce evidence-based strategies to enhance donor safety and ensure sustainability of blood supply. We are the grant holders and managers of this unit.
Collaborator Contribution The Unit is building and exploiting exceptionally large and detailed "living laboratories" of healthy participants who consent to frequent and active engagement in research studies (eg, recall-by-genotype, periodic re-attendance, wearing of devices, linkage with e-health records). For example, leveraging our strategic relationship with NHSBT, we have commenced linkage of >1M blood donors to e-health records. As a proof-of-concept study, we have already enrolled 50,000 donors into the INTERVAL Study in which we have commenced cohort-wide 15X whole genome sequencing, measured >5000 molecular phenotypes (eg, lipids, metabolites, proteins), conducted an advanced analysis of the cellular composition of the blood, employed accelerometry devices at scale and measured genome-wide genotypes.
Impact The goals of this new Unit are to combine cutting-edge tools from genomics, biology and population health science to address key questions about the aetiology of important disorders (such as the health consequences of iron deficiency), to improve the safety and precision of blood donation, and to build and use major genomic resources that enable the study of important chronic diseases of wider relevance. This unit combined the disciplines of clinical studies, functional genetics, epidemiology and statistics/bioinformatics.
Start Year 2015
 
Description NIHR BTRU in Donor Health and Genomics 
Organisation University of Oxford
Department Nuffield Division of Clinical Laboratory Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge is a cross-disciplinary unit established to address major questions about the health of blood donors and produce evidence-based strategies to enhance donor safety and ensure sustainability of blood supply. We are the grant holders and managers of this unit.
Collaborator Contribution The Unit is building and exploiting exceptionally large and detailed "living laboratories" of healthy participants who consent to frequent and active engagement in research studies (eg, recall-by-genotype, periodic re-attendance, wearing of devices, linkage with e-health records). For example, leveraging our strategic relationship with NHSBT, we have commenced linkage of >1M blood donors to e-health records. As a proof-of-concept study, we have already enrolled 50,000 donors into the INTERVAL Study in which we have commenced cohort-wide 15X whole genome sequencing, measured >5000 molecular phenotypes (eg, lipids, metabolites, proteins), conducted an advanced analysis of the cellular composition of the blood, employed accelerometry devices at scale and measured genome-wide genotypes.
Impact The goals of this new Unit are to combine cutting-edge tools from genomics, biology and population health science to address key questions about the aetiology of important disorders (such as the health consequences of iron deficiency), to improve the safety and precision of blood donation, and to build and use major genomic resources that enable the study of important chronic diseases of wider relevance. This unit combined the disciplines of clinical studies, functional genetics, epidemiology and statistics/bioinformatics.
Start Year 2015
 
Description NMR Metabolomics 
Organisation Brainshake
Country Finland 
Sector Private 
PI Contribution Provided samples from 50,000 participants in INTERVAL study.
Collaborator Contribution Assays complete for all 50,000 samples, ~240 metabolites measured.
Impact Publication manuscripts in preparation
Start Year 2014
 
Description Novartis 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution 1) Characterization of associations of Lp(a)-related variants with Lp(a) concentration 2) Characterization of associations of Lp(a)-related variants with coronary heart disease (CHD) risk 3) Inclusion of additional results on some Lp(a)-related variants with CHD risk 4) Assessment of potential additivity of Lp(a) pathways and LDL-C pathways in CHD 5) "Phenome scanning" to explore broader phenotypic consequences of genetic Lp(a)-lowering
Collaborator Contribution Financial support of £355,000
Impact Publication: 10.1001/jamacardio.2018.1470 Novartis Trial Board Presentation (Adam Butterworth) IGMM Seminar University of Edinburgh (Adam Butterworth)
Start Year 2017
 
Description Proteomics - SomaLogic 
Organisation SomaLogic
Country United States 
Sector Private 
PI Contribution We have provided 3500 samples from the INTERVAL study for analysis on SomaLogic's platform (approx. 1129 proteins measured).
Collaborator Contribution Analysis of 3500 samples at a discounted price
Impact Receiving data from platform; publication manuscripts in preparation
Start Year 2015
 
Description Sanger Sequencing 
Organisation The Wellcome Trust Sanger Institute
Department Human Genetics
Country United Kingdom 
Sector Academic/University 
PI Contribution Provision of samples from INTERVAL Study and collaboration on analysis and publication manuscript preparation
Collaborator Contribution Whole genome and whole exome sequencing of samples from the INTEVAL Study
Impact Data received on ~4500 samples so far
Start Year 2015
 
Description The Cambridge-Baker Systems Genomics Initiative 
Organisation Baker IDI Heart and Diabetes Institute
Country Australia 
Sector Academic/University 
PI Contribution Contributions include expertise and input from my research team to identify and explore the opportunities for joint research collaboration to 1) meet the next generation of challenges in cardiometabolic disease screening and prevent 2) identification and characterisation of drug targets through multi-omic analysis 3) development of transformational analytic methods that will drive the subsequent research epoch. My group will provide data analysis capacity and training resources to the Baker institute. Other contributions include: paying 50% of employment costs of Prof Inouye, 1 FTE Postdoc position, able to supervise PhD students;, $30,00pa travel support, accommodation and IT facilities for the CBSGI. This collaboration will be initially for five years and started June 2018.
Collaborator Contribution The Baker Node will provide access to datasets, and other intellectual resources. Furthermore the Baker Node will provide 50% of the employment costs of Prof Inouye, 3 x 1FTE postdoc positions, travel support ($30,000 pa), accommodation and IT facilities for the CBSGI, access grant funding to expand capacity.
Impact Publications: https://doi.org/10.1371/journal.pgen.1007607 https://doi.org/10.1016/j.jacc.2018.07.079 10.7554/eLife.35856 https://doi.org/10.1161/CIRCGEN.118.002234 https://doi.org/10.1093/nar/gky780 https://doi.org/10.1016/j.chom.2018.08.005 https://doi.org/10.1038/s41588-018-0117-9 Committees: Cambridge Baker Experimental Working Group Target validate of in silico discoveries University of Cambridge / Baker Institute Selection Committee: MRC PhD studentships in Data Science / Artificial Intelligence University of Cambridge Symposiums/seminars - Health Data Research UK: Cambridge, Polygenic risk scores and multiple -omics, Cambridge - Alfred Grand Rounds, Genomic risk and precision medicine: Or how I learned to stop worrying and love computational biology, Melbourne - Million Veterans Project Retreat, Integrative omics analysis, Downing College, Cambridge
Start Year 2018
 
Description Briefing pharmaceutical companies 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? Yes
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presented work on key findings and published papers.

Raised awareness of topic and/or instigated discussion/further research/funding
Year(s) Of Engagement Activity 2010,2011,2012,2013,2014
 
Description Mendelian Randomization Conference From Population Health to Pharmaceutical Developments 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A conference on aetiological epidemiology and causality in population health and clinical medicine
Year(s) Of Engagement Activity 2015
 
Description A short talk on the genetics of heart disease and risk calculation both for environmental and genetic factors at the Cambridge Science Festival 2017. 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact A short talk on the genetics of heart disease and risk calculation both for environmental and genetic factors at the Cambridge Science Festival 2017. Intended to disseminate research to the general public.
Year(s) Of Engagement Activity 2017
 
Description Alan Turing Institute presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presentation of findings from scientific research
Year(s) Of Engagement Activity 2015
 
Description Amgen Lipoprotein(A) Advisory Board 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Attendance in an advisory capacity at Amgen's Lipoprotein(a) advisory board meeting. Chance to provide insight and perspective to Industry on this topic.
Year(s) Of Engagement Activity 2017
 
Description Article in NHSBT's The Donor Magazine (BTRU, INTERVAL, COMPARE) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Contributed an article to one of our partners - NHS Blood and Transplant's - magazines, which has significant reach across their donor groups and the research reported has impacted NHSBT strategy and processes.
Year(s) Of Engagement Activity 2018
URL https://www.blood.co.uk/news-and-campaigns/the-donor-autumn-2018/new-haemoglobin-test/
 
Description Ask a Scientist (Amy Mason) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Schools
Results and Impact A Skype call - 'Ask a Scientist' - with a group of 30 American school children, aged 9 years old.
Year(s) Of Engagement Activity 2018
 
Description Astra Zeneca rountable discussion re CVD research 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presentation given at Roundtable Discussion focussed on Industry funded research programme ( One Brave Idea) to Industry colleagues.
Year(s) Of Engagement Activity 2017
 
Description AstraZeneca Annual Genomics Partners Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Talk on ongoing recall-studies with volunteers from the Cambridge BioResource, delivered to stakeholders at AstraZeneca.
Year(s) Of Engagement Activity 2006,2017
 
Description AstraZeneca Annual Genomics Partners Workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Keynote speech given at an Astra Zeneca partners Conference which sparked debate.
Year(s) Of Engagement Activity 2017
 
Description AstraZeneca Centre for Genomics Research Annual Collaborators meeting (Dr Adam Butterworth) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Industry/Business
Results and Impact Presentation with title "using genomic and molecular information in the INTERVAL study to inform AZ therapeutic target prioritisation" at the AstraZeneca Centre for Genomics Research Annual Collaborators. Presenting the results of the collaboration with AstraZeneca and get their feedback, to inform future work.
Year(s) Of Engagement Activity 2018
 
Description BBC Radio Cambridgeshire interview 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Radio interview about a paper we had recently published in the European Heart Journal about obesity and physical fitness.
Year(s) Of Engagement Activity 2017
 
Description BBC Radio Wales Interview (Clare Oliver-Williams) 
Form Of Engagement Activity A broadcast e.g. TV/radio/film/podcast (other than news/press)
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Public/other audiences
Results and Impact Discussed research project findings on BBC Radio Wales morning show. Increased awareness/knowledge of cardiovascular disease.
Year(s) Of Engagement Activity 2018
 
Description BHF Cambridge CRE Annual research meeting 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Annual British Heart Foundation Cambridge Centre visit - presentation overview of theme (Population Sciences) which sparked questions and discussion.
Year(s) Of Engagement Activity 2017
 
Description BHF Cambridge Centre for Cardiovascular Research Excellence Annual Symposium 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Annual BHF Cambridge Centre for Cardiovascular Research Excellence Symposium. Session of population Chaired which sparked questions and debate.
Year(s) Of Engagement Activity 2017
 
Description BTRU Advisory Committee Workshop (BTRU) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact An opportunity for members of the public serving on a formal committee to network with researchers and each other and to hear updates about research being conducted. Feedback from members of the public was very positive - they reported having a much better understanding about our research.
Year(s) Of Engagement Activity 2018
 
Description BTRU Directors Meeting (Emanuele Di Angelantonio) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Third sector organisations
Results and Impact Meeting between the leaders of the four Blood and Transplant Research Units with NIHR and NHSBT, in order to discuss research progress and strategy.
Year(s) Of Engagement Activity 2018
 
Description BTRU Seminar Series (BTRU) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Speakers invited from around the world to talk about their research to academics, students, funding body representatives, charity representatives and members of the public. Numerous research collaborations have arisen from these talks, as well as increased awareness and confidence in members of the public, who have been given the opportunity to interact with world-class researchers.
Year(s) Of Engagement Activity 2018
URL http://www.donorhealth-btru.nihr.ac.uk/btru_events/
 
Description BTRU and Study Management Committee meetings (BTRU, STRIDES) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact A formal meeting between researchers, funding body representatives, students and members of the public, in order to discuss the Unit's research or design studies. The meetings have enabled better collaboration and influenced study design, through public input.
Year(s) Of Engagement Activity 2018
 
Description Big Data Institute presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Presented research at the big data institute in Oxford, this lead to questions and collaborations on a new direction of research.
Year(s) Of Engagement Activity 2017
 
Description British Heart Foundation, Health Informatics presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presented work on key findings on published papers

Raised awareness of topic and/or instigated discussion/further research
Year(s) Of Engagement Activity 2014
 
Description CAPABLE Bangladesh Launch 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Policymakers/politicians
Results and Impact Bangladesh launch of CAPABLE programme, talks given, press spoken to and site visited. Generated lots of debate and in country press articles.
Year(s) Of Engagement Activity 2018
 
Description CAPABLE General Assembly (John Danesh) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Annual general assembly of CAPABLE programme, gathering of all collaborators, staff members, supporters, extended network, donors and other stakeholders. Talks, debates, working groups
Year(s) Of Engagement Activity 2018
URL http://www.capable-bangladesh.org/capable-in-popular-media/meeting-september-2018-uk/
 
Description CAPABLE workshop in Bangladesh (Emanuele Di Angelantonio) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Travel to Dhaka to plan implementation of CAPABLE study, with Scientific Planning Committee Meeting, site visits and meeting collaborators
Year(s) Of Engagement Activity 2018
 
Description Cambridge BioResource Open Evening 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Study participants or study members
Results and Impact Talk on the scientific background of the recall-studies, delivered to members of the volunteer panel of the Cambridge BioResource. The purpose was to introduce the research to the volunteers, answer questions, and invite them to participate in the studies.
Year(s) Of Engagement Activity 2017
URL https://www.cambridgebioresource.group.cam.ac.uk/
 
Description Cambridge GCRF launch event 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Policymakers/politicians
Results and Impact Visit by politicians (Joe Johnson) and RCUK representatives to promote the GCRF projects funded at the University of Cambridge, including presentations to these stakeholders.
Year(s) Of Engagement Activity 2017
 
Description Cambridge Science Festival 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Helping out at the "Hands On" stall by the Division of Cardiovascular Medicine, giving a talk with 'Out-thinkers' and running a live action game event aimed at teaching 30 school children about the complexity of dealing with emerging epidemics.
Year(s) Of Engagement Activity 2018
URL https://www.sciencefestival.cam.ac.uk/about/past-festivals/2018-festival
 
Description Cambridge Science Festival (various) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact - Volunteered for a 'hands-on' stand at the festival, doing activities with children about the cardiovascular system.[Susan Burton, Clare Oliver-Williams, Amy Mason]
- Gave a talk to the public (including Q&A) about relations between day-to-day cardiovascular functioning and thoughts, feelings, and behaviours. [Philippe Gilchrist]
- Gave a talk to the public as part of Out Thinkers - just like white light is made by all the colour of the rainbow, so Science is made by the contributions of a cast of thousands. Meet some of these researchers in an informal setting and we hope to provide some laughs and a lot of science! Out Thinkers serves to showcase the talent of LGBT researchers, providing a platform where people can talk about their scientific work while truly being themselves.[Amy Mason]
- Workshops for children using a game called Pathogen (live action game aims to give you an understanding of epidemics and the logistics of global disease prevention by putting you in the shoes of a global organisation responding to the outbreak of a new disease). [Amy Mason]
Year(s) Of Engagement Activity 2018
URL https://www.sciencefestival.cam.ac.uk/about/past-festivals/2018-festival
 
Description Cambridge University-Baker Institute Partnership (Mike Inouye) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact A new partnership with Cambridge University will significantly expand the capabilities of one of Australia's leading medical research institutes, Baker Heart and Diabetes Institute, to harness big data to target approaches in disease prediction and personalised medicine.
Year(s) Of Engagement Activity 2018
URL https://baker.edu.au/news/media-releases/cambridge-university-partnership
 
Description Cambridge-Baker Experimental Working Group (Mike Inouye) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Working group to discuss research strategies.
Year(s) Of Engagement Activity 2018
 
Description Cambridge-Singapore Symposium (John Danesh) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Cambridge-Singapore Symposium in Addenbrookes with National University of Singapore covering various topics including cardiovascular disease aimed at clinical staff in the Hospital.
Year(s) Of Engagement Activity 2019
 
Description Cardiovascular Medicine Series, University of Oxford 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presented work on key findings and published papers.

Raised awareness of topic and/or instigated discussion/further research
Year(s) Of Engagement Activity 2011
 
Description Clinical Grand Rounds 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Health professionals
Results and Impact Presented work on key findings

Raised awareness of topic and/or instigated discussion
Year(s) Of Engagement Activity 2010,2011,2012
 
Description Cochrane Lecture 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presented work on key findings on published papers

Raised awareness of topic and/or instigated discussion/further research
Year(s) Of Engagement Activity 2014
 
Description Collaborative workshop MRC Biostatistics 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presentation of findings from scientific research
Year(s) Of Engagement Activity 2015
 
Description EMBL and GRL Framework Partnership Agreement Renewal Event (John Danesh) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Professional Practitioners
Results and Impact EMBL and GRL Framework Partnership Agreement Renewal Event - Short talks regarding successful joint projects between EMBL-EBI and GRL.
Year(s) Of Engagement Activity 2018
 
Description European Researchers Night (Clare Oliver-Williams) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Engaging children's activities about being heart healthy. Increased awareness/knowledge of cardiovascular disease.
Year(s) Of Engagement Activity 2018
URL https://ec.europa.eu/research/mariecurieactions/news/2018/european-researchers-night-2018-2019_en
 
Description European Society of Human Genetics (Barcelona) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Third sector organisations
Results and Impact Oral presentation at the European Society of Human Genetics (Barcelona, 2016).
Year(s) Of Engagement Activity 2016
 
Description First International Cohorts Summit (John Danesh) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact first forum for large-scale longitudinal cohorts worldwide to share best practices, discuss data sharing, explore standards, discuss common challenges, and explore the potential for a larger collaborative sequencing strategy.
Year(s) Of Engagement Activity 2018
 
Description Gave talk at Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA (Emanuele Di Angelantonio) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Postgraduate students
Results and Impact Travelled to Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, USA and gave a talk on "Cardiovascular disease epidemiology in Cambridge: from aetiology to risk prediction"
Year(s) Of Engagement Activity 2018
 
Description Genome Sequencing Project 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presentation given to an event with Astra Zeneca regarding potential collaboration involving strategic genome sequencing projects.
Year(s) Of Engagement Activity 2017
 
Description Genomics of Common Diseases conference (Baltimore) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Oral presentation at Genomics of Common Diseases conference (Baltimore)
Year(s) Of Engagement Activity 2016
 
Description Giving seminar at Institute for Biomedicine EURAC, Bolzano, Italy (Emanuele Di Angelantonio) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Travel to Institute for Biomedicine in Italy to give presentation to students and researchers on "Cardiovascular disease epidemiology in Cambridge: from aetiology to risk prediction"
Year(s) Of Engagement Activity 2018
 
Description HDL Causality Genetics 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presented work on key findings on published papers

Raised awareness of topic and/or instigated discussion/further research
Year(s) Of Engagement Activity 2014
 
Description HDRUK Announcement as a chosen substantive site of HDRUK 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact National and local press release to publicise Cambridge being chosen as a substantive site of HDRUK.
Year(s) Of Engagement Activity 2018
 
Description Hands-on workshops for children (Pathogen) (Amy Mason) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Schools
Results and Impact Hands-on workshops for children, using the game Pathogen - a live action game which aims to give you an understanding of epidemics and the logistics of global disease prevention by putting you in the shoes of a global organisation responding to the outbreak of a new disease. The participants will be split up into small teams who will need to work together to keep this potentially dangerous disease under control. Each team will have its own activities to prioritise and complete, using a combination of statistics, medicine, biology and creative communication to save the world!"
Year(s) Of Engagement Activity 2018
 
Description Harvard School of Public Medicine 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presented work on key findings on published papers.

Raised awareness of topic and/or instigated discussion/further research
Year(s) Of Engagement Activity 2011
 
Description Hills Road Sixth Form College - Big Biology Day (BTRU) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Public/other audiences
Results and Impact Information about our research and hands-on activities delivered for children considering their career options. Increased awareness of career opportunities in the sciences, beyond becoming an academic, and an opportunity to tell the public about our research.
Year(s) Of Engagement Activity 2018
 
Description IGMM Seminar University of Edinburgh (Adam Butterworth) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Dr. Adam Butterworth gave the seminar "combining genomics and plasma proteomics to inform disease aetiology and therapeutic targets" as part of the IGMM Seminar Series. These weekly seminars attract distinguished scientists from around the world working in the fields of genetics, molecular medicine and cancer research, and whose research complements that being done at IGMM. Outcomes are improved awareness of research topics and findings, networking, making new linkages with other research.
Year(s) Of Engagement Activity 2018
 
Description Institute of Public Health Showcase 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented work on key findings and published papers.

Raised awareness of topic and/or instigated discussion/further research
Year(s) Of Engagement Activity 2012,2014
 
Description Internal newsletters - Donor Population Health (Emanuele Di Angelantonio) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact An internal newsletter, shared with partnership colleagues (NHSBT), to share relevant information about research areas of interest.
Year(s) Of Engagement Activity 2018
 
Description International Genetic Epidemiology Conference, Toronto 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Third sector organisations
Results and Impact Presentation of research findings at the International Genetic Epidemiology Conference, Toronto.
Year(s) Of Engagement Activity 2016
 
Description MRC PhD studentships in Data Science / Artificial Intelligence (Mike Inouye) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact Selection committee for awarding PhD studentships in data science/artificial intelligence.
Year(s) Of Engagement Activity 2018
 
Description MRC presentation 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation of findings from scientific research
Year(s) Of Engagement Activity 2015
 
Description Media Interviews 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Media (as a channel to the public)
Results and Impact Presented work on key findings on published papers.

Raised awareness of topic and/or instigated discussion/further research
Year(s) Of Engagement Activity 2008,2009,2010,2011,2012
 
Description NIHR BTRU & NHSBT PPIE Meetings (BTRU) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Third sector organisations
Results and Impact An opportunity for patient and public involvement and engagement (PPIE) professionals to meet with funding body representatives and charity representatives, to collaborate and discuss best practice.
Year(s) Of Engagement Activity 2018
 
Description NIHR BTRU Training Day 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Poster presentation on research conducted in the BTRU in Donor Health and Genomics, delivered to members of the general public and other scientists. The purpose was to engage the public in the ongoing research.
Year(s) Of Engagement Activity 2017
URL http://www.donorhealth-btru.nihr.ac.uk/
 
Description NIHR Blood and Transplant Research Unit Training Day (Emanuele Di Angelantonio, BTRU) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Postgraduate students
Results and Impact Workshop to allow clinicians, scientists, managers, directors, stakeholders and students to (1) explore how research activities support operational strategies for the Blood and Transplant Research Units, (2) update each other on research progress and (3) discuss collaborations.
Year(s) Of Engagement Activity 2018
 
Description Newsletter to update blood donor centre staff on study progress (BTRU) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Third sector organisations
Results and Impact A newsletter to update Blood Donor Centre staff, who managed several of the Unit's studies, on research outcomes following the completion of the studies. Increased awareness about our research and enthusiasm to collaborate for future studies.
Year(s) Of Engagement Activity 2018
 
Description Newsletters to update study participants (BTRU, INTERVAL) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Study participants or study members
Results and Impact Periodic newsletters sent to study participants, in order to update them on research projects made possible by their participation. Newsletters have revitalised discussion about studies (some of which have finished but the data can be used in myriad way) and ideas for representing the research on the study websites.
Year(s) Of Engagement Activity 2018
URL http://www.intervalstudy.org.uk/news-2/
 
Description Novartis Trial Board Presentation (Adam Butterworth) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact A presentation to enlighten about research activities, network and build collaborations.
Year(s) Of Engagement Activity 2018
 
Description PROCARDIS Lp(a) Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presented work on key findings and published papers.

Raised awareness of topic and/or instigated discussion/further research
Year(s) Of Engagement Activity 2011
 
Description Poster discussion at the ESC Barcelona Conference 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Lead discussion at the ESC Barcelona Conference during poster presentation to encourage questions and consideration of topic.
Year(s) Of Engagement Activity 2017
 
Description Present at the donor session at the annual BBTS conference, Glasgow 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact The audience in the donor session will comprise of medical and nursing professionals involved in blood donation. It is an educational programme to promote understanding and discussion in this topic.
Year(s) Of Engagement Activity 2017
 
Description Presentation at AHA Scientific Sessions in Chicago (Emanuele Di Angelantonio) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Poster Presentation: Cardiovascular Disease Risk Prediction Using Machine Learning: A Prospective Cohort Study of 423,604 Participants
Year(s) Of Engagement Activity 2018
 
Description Presentation at BHF Centre of Excellence meeting 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presentation of findings from scientific research
Year(s) Of Engagement Activity 2015
 
Description Presentation at BRC Scientific Advisory Board 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Presentation of findings from scientific research
Year(s) Of Engagement Activity 2015
 
Description Presentation at Peking University Health Science Center, China 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Discussion on NSFC funded project of "Cardiovascular risk prediction for the Chinese population using big data: from discovery to application" for education and enagement.
Year(s) Of Engagement Activity 2017
 
Description Presentation at Wellcome Trust Target Validation Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presentation of findings from scientific research
Year(s) Of Engagement Activity 2015
 
Description Presentation at pre-meet on TRANSPOSE project at Sanquin, Amsterdam (Emanuele Di Angelantonio) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Meeting with international collaborators to update and discuss WP4 section of TRANSPOSE study
Year(s) Of Engagement Activity 2018
 
Description Presentation at the Australian Red Cross Blood Service 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Patients, carers and/or patient groups
Results and Impact Presentation to audience of blood service staff who work in predominantly donor collection, recruitment and the communication and marketing team, the researchers working within the blood service, related university partners and representatives from government agencies.
Year(s) Of Engagement Activity 2017
 
Description Presentation at the European Bioinformatics Institute 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presentation of findings from scientific research
Year(s) Of Engagement Activity 2015
 
Description Presentation for Sysmex Japan visit (Emanuele Di Angelantonio) 
Form Of Engagement Activity Participation in an open day or visit at my research institution
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Opportunity for Cambridge to further strengthen its leading role on blood cell genomics and to bring tangible improvements to the diagnostic value of the Full Blood count analysis.   
Year(s) Of Engagement Activity 2018
 
Description Presentation to CTSU in Oxford 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Other audiences
Results and Impact Presented research at the CTSU in Oxford, this lead to many questions and post-presentation discussions and suggested new areas of research for some in the audience. Also lead to additional follow up from individuals in the following months showing interest in my area of research.
Year(s) Of Engagement Activity 2017
 
Description Presentation to Takeda 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presentation of findings from scientific research
Year(s) Of Engagement Activity 2015
 
Description Presenting at BEST Collaborative meeting in Florence (Emanuele Di Angelantonio) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Meeting of practitioners to discuss Biomedical Excellence for Safer Transfusion and present new research and up to date techniques
Year(s) Of Engagement Activity 2018
 
Description Presenting at EUROPEAN CONFERENCE ON DONOR HEALTH & MANAGEMENT 2018 in Copenhagen (Emanuele Di Angelantonio) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Chairing a session on Donor Health Studies and participating in a debate on IRON AND DONOR HEALTH - DIFFERENT APPROACHES TO MEASURING HB IN BLOOD DONORS INTERNATIONALLY with an update on the COMPARE study
Year(s) Of Engagement Activity 2018
 
Description Presenting at IBST Conference, Toronto (Emanuele Di Angelantonio) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presenting in the Donors & Donation - Donor Safety Session to practitioners on new research and up to date techniques in this field.
Year(s) Of Engagement Activity 2018
 
Description Presenting poster session at Cambridge-Harvard Cardiorespiratory Research Meeting 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact The purpose of the meeting was to showcase the high quality research in Cambridge that might foster future collaborations between the two universities.
Year(s) Of Engagement Activity 2017
 
Description Press release and media enquiries (Clare Oliver-Williams) 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Press release about research presented at a conference, leading to media enquiries. It was covered in national papers (e.g. the independent) as well as international press (e.g. Newsweek). Increased awareness/knowledge of cardiovascular disease.
Year(s) Of Engagement Activity 2018
URL https://www.newsweek.com/kids-linked-heart-disease-risk-mothers-according-new-study-956066
 
Description Public involvement - requesting comments for study documentation (BTRU) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Numerous opportunities for members of our formal working groups to provide comment on our study documents and research. Comments were fed back to researchers and incorporated.
Year(s) Of Engagement Activity 2018
 
Description Renewal of MRC/BHF Programme Grant 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Supporters
Results and Impact Visit by Professor Chris Whitty, presentation given on BRC population health
Year(s) Of Engagement Activity 2017
 
Description Research article for the Conversation (Clare Oliver-Williams) 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Wrote an article for the Conversation about research, which was re-published in the Sun, blogs and translated into French. Increased awareness/knowledge of cardiovascular disease.
Year(s) Of Engagement Activity 2018
URL https://theconversation.com/avoir-des-enfants-augmenterait-le-risque-de-maladies-cardio-vasculaires-...
 
Description Research meetings with BTRU Advisory Committee members (BTRU) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach Regional
Primary Audience Study participants or study members
Results and Impact Meetings between research leads and members of the public serving on an Advisory Committee, a formal group to ensure public involvement in our research activities. Members of the public have made significant contributions to the design of our studies and impacted the way that staff and students interact with public involvement and engagement activities.
Year(s) Of Engagement Activity 2018
URL http://www.donorhealth-btru.nihr.ac.uk/involved/ppi/
 
Description Speaker at workshop at Beijing Institute of Heart Lung and Blood Vessel Diseases, China 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Invited speaker for the workshop of "diagnosis and prognosis of survival for aortic dissection" with a view to discussion on potential collaboration
Year(s) Of Engagement Activity 2017
 
Description Speaking at 1st International Symposium of Translation Medicine Luhe hospital in Beijing (Emanuele Di Angelantonio) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Traveled to Luhe hospital in Beijing to deliver up-to-date knowledge, technology and research findings to the medical field
Year(s) Of Engagement Activity 2018
 
Description Speaking at BEST Collaborative meeting in Newport, USA (Emanuele Di Angelantonio) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Meeting of practitioners to discuss Biomedical Excellence for Safer Transfusion and present new research and up to date techniques
Year(s) Of Engagement Activity 2018
 
Description Talk - Alfred Grand Rounds, Genomic risk and precision medicine (Mike Inouye) 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Talk to researchers about the challenges of working in computational biology.
Year(s) Of Engagement Activity 2018
 
Description Talk at AstraZeneca 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Presentation of findings from scientific research
Year(s) Of Engagement Activity 2015
 
Description Talk at AstraZeneca Genomic Partners Workshop 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Talk about my scientific research at a meeting of industry and academia
Year(s) Of Engagement Activity 2017
 
Description Talk at British Atherosclerosis Society Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Talk about my scientific research
Year(s) Of Engagement Activity 2017
 
Description Talk at Genomics of Common Diseases conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Talk about my scientific research at a conference
Year(s) Of Engagement Activity 2017
 
Description Talk at NHSBT blood donor studies conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Professional Practitioners
Results and Impact Talk about my scientific research
Year(s) Of Engagement Activity 2017
 
Description Talk at NIHR Stroke Research Conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Talk about my scientific research at a conference
Year(s) Of Engagement Activity 2017
 
Description Talk at Therapeutic Target Validation conference 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact Talk about my scientific research at a conference
Year(s) Of Engagement Activity 2017
 
Description Talk at cardiovascular seminar series, Addenbrookes hospital, Cambridge 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach Local
Primary Audience Professional Practitioners
Results and Impact The audience were scientists, clinical fellows and students in cardiovascular research. The purpose was to educate and discuss current research.
Year(s) Of Engagement Activity 2017
 
Description Teaching at Short Course in Dhaka, Bangladesh (Emanuele Di Angelantonio) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Teaching on Short Course in Dhaka, Bangladesh organised by UK Universities to extend knowledge and educate as part of CAPABLE study
Year(s) Of Engagement Activity 2018
 
Description Tiered Consent Workshops (Emanuele Di Angelantonio) 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact As part of a research project on developing a tiered consent process for blood donors, members of the public were invited to participate in generating ideas, giving opinions and enriching discussions with stakeholders and researchers.
Year(s) Of Engagement Activity 2018
 
Description Twitter accounts for the Cardiovascular Epidemiology Unit, Blood and Transplant Research Unit and individual researchers 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Increased activity of all Twitter accounts, with the aim of engaging more members of the public and informing about our research outcomes. Increase in followers and awareness/knowledge about our research and opportunities in which to get involved (studentships, public involvement/engagement, etc).
Year(s) Of Engagement Activity 2018
URL https://twitter.com/cambridge_ceu?lang=en
 
Description Update at TRANSPOSE Meeting at Finnish Red Cross Blood Service in Helsinki (Emanuele Di Angelantonio) 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Meeting with international collaborators to update and discuss TRANSPOSE study
Year(s) Of Engagement Activity 2018
 
Description Website for Cardiovascular Epidemiology Unit, Blood and Transplant Research Unit, various studies and research partnerships 
Form Of Engagement Activity Engagement focused website, blog or social media channel
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Public/other audiences
Results and Impact Research activities written for the public (removing acronyms, short-hand, etc) and addition of Patient and Public Involvement and Engagement pages (see URL below). Other websites disseminate information about who we are and what w do, how to get involved (studentships, public involvement/engagement), partnerships and publications (as a means of sharing outcomes from our research activities).
Year(s) Of Engagement Activity 2018
URL http://www.donorhealth-btru.nihr.ac.uk/involved/
 
Description Wellcome Trust Sanger Institute 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Professional Practitioners
Results and Impact Presented work on key findings.

Raised awareness of topic and/or instigated discussion/further research
Year(s) Of Engagement Activity 2011,2012,2013
 
Description Workshop on genetic studies in the Bangladeshi population 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presented work on key findings on published papers

Raised awareness of topic and/or instigated discussion/further research
Year(s) Of Engagement Activity 2014
 
Description Workshop on genetic studies in the Pakistani population 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Type Of Presentation Keynote/Invited Speaker
Geographic Reach International
Primary Audience Other academic audiences (collaborators, peers etc.)
Results and Impact Presented work on key findings and published papers.

Raised awareness of topic and/or instigated discussion/further research
Year(s) Of Engagement Activity 2010
 
Description presentation to stroke research audience 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Other audiences
Results and Impact Presented research to a stroke research audience and had many questions a lot of enthusiasm for the work and new collaborations.
Year(s) Of Engagement Activity 2017